Shanghai Luxiangyi has supplied eight centrifuges to Anzhao, a major pharmaceutical company, for vaccine research and development.

　　Regarding the highly publicized vaccine incident earlier on, on September 7, the National Medical Products Administration issued a document announcing the results of risk assessments conducted on all 45 existing vaccine manufacturers nationwide. The findings indicate that the production of vaccine products at these companies is proceeding normally (excluding Changsheng Bio-technology), and no issues concerning vaccine quality or safety have been identified. At the same time, the NMPA stated that it will continue to maintain a stringent regulatory stance on vaccine products, further improve the quality management system, strengthen risk control measures, intensify spot inspections and follow-up monitoring, and standardize vaccine production practices within the industry.

　　Vaccines have saved countless lives. Yet at the same time, if problematic vaccines were to emerge, countless lives could be put at risk. It is understood that vaccine development is extremely costly. As a result, many companies, after making massive upfront investments, may face the temptation to shift their focus to “recouping costs and maximizing profits” once large-scale production begins. Therefore, strengthening vaccine regulation, enhancing risk management, and improving the technological level and quality of equipment used in vaccine research and production are crucial for ensuring higher vaccine quality.

　　The author has learned that, in order to uphold our conscience, help pharmaceutical companies strike a balance and make the right choices between profit and social responsibility, and provide the domestic market with safe and reliable vaccine products, Shanghai Luxiangyi Centrifuge Instrument Co., Ltd. is supplying eight DL-6MS units to a large pharmaceutical R&D company that has achieved significant success in the development of new vaccines. High-capacity refrigerated centrifuge 。

DL-6MS High-Capacity Refrigerated Centrifuge

　　According to reports, the company served by Shanghai Luxiangyi this time is not driven by commercial interests but rather by scientific research, aiming to inspire scientists and always putting patients first. As a pharmaceutical company, it bravely shoulders its social responsibility and has set an exemplary standard for numerous domestic pharmaceutical companies.

　　The DL-6M high-capacity refrigerated centrifuge, developed and manufactured by Shanghai Luxiangyi, is specially designed for customers with large-volume requirements. This model boasts a substantial sample-processing capacity and is an essential piece of equipment in fields such as central blood banks, pharmaceuticals, and bioengineering.

　　This centrifuge boasts a maximum capacity of 1200 ml × 6 and features dual-channel temperature control—both cooling and heating—to precisely maintain the optimal separation temperature for component blood. It is microcomputer-controlled, driven by a high-torque AC variable-frequency motor, ensuring stable operation, low noise levels, and high rotational speed accuracy. The centrifuge employs an imported high-performance compressor unit and uses the fluorine-free refrigerant R404a, meeting environmental protection standards and delivering excellent cooling performance. It features a touch-panel interface with programmable operation; host operating parameters can be set according to user needs and are automatically saved. A large-screen LCD display and digital readout options provide a user-friendly interface that is simple and convenient to operate. Real-time conversion and setting between rpm and RCF measurements ensure quick and hassle-free operation. Equipped with an electronic door lock, the centrifuge offers multiple protective functions, including automatic door-locking, overspeed protection, overtemperature protection, and imbalance detection, as well as an automatic alarm system for fault detection, making it safe and reliable. The centrifuge comes with 10 pre-programmed acceleration/deceleration curves, allowing users to customize the acceleration and deceleration times as needed. It utilizes an integral sealing ring made of food-grade silicone rubber that complies with CMP certification, and the centrifuge has obtained U.S. FDA approval.

　　Shanghai Luxiangyi is a specialized manufacturer of centrifuges. Since its establishment more than four decades ago, the company has been dedicated to the R&D and production of centrifuges, consistently adhering to the quality principle of "quality first, reputation paramount," and providing customers with high-quality, high-tech products. Over the past four decades of development, Shanghai Luxiangyi has built up strong technical capabilities. Its equipment is meticulously crafted, boasts stable performance, and features innovative designs, making it highly popular in the market. In this collaboration with relevant vaccine companies, Shanghai Luxiangyi is fully capable of taking on this important responsibility.

　　“After receiving the assignment, our R&D team has been continuously communicating and collaborating with enterprises, striving to perfect the equipment and contribute our part to the vaccine industry,” said the relevant staff member. Vaccine quality is closely linked to the health of countless families. The shocking cases involving substandard vaccines underscore the importance of enhancing vaccine quality and ensuring vaccine safety. To achieve this goal, pharmaceutical and equipment companies must always put patients first. In particular, pharmaceutical equipment manufacturers should continually upgrade their technological capabilities, providing robust equipment support to pharmaceutical companies and making every effort to “prioritize technical solutions whenever they can effectively address the issue.”